Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Suhwan Chang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0282-0120; OpenAlex author ID A5024096667. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. The Galectin-3-binding protein promotes angiogenesis in pancreatic cancer via simultaneous upregulation of VEGFA and direct HUVEC activation mediated by and VA… Last author DOI 10.1186/s12964-026-02801-7↗
  2. S100A4 promotes collective invasion of pancreatic ductal adenocarcinoma and its blockade suppresses metastasis. Last author DOI 10.1186/s12964-026-03052-2↗
  3. Retraction: Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced … Co-author DOI 10.18632/oncotarget.28813↗
  4. Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Last author DOI 10.1073/pnas.2119048119↗
  5. Metagenomic analysis of gut microbiome reveals a dynamic change in Alistipes onderdonkii in the preclinical model of pancreatic cancer, suppressing its prolife… Last author DOI 10.1007/s00253-021-11617-z↗
  6. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model. Last author DOI 10.3390/cells10102734↗
  7. A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. Last author DOI 10.1016/j.canlet.2019.08.002↗
  8. A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer c… Last author DOI 10.1002/1878-0261.12364↗
  9. Genetic and metabolic comparison of orthotopic and heterotopic patient-derived pancreatic-cancer xenografts to the original patient tumors. Co-author DOI 10.18632/oncotarget.23567↗
  10. Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. Co-author DOI 10.1186/s12935-017-0416-8↗
  11. Downregulation of X-linked inhibitor of apoptosis protein by '7-Benzylidenenaltrexone maleate' sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. Co-author DOI 10.18632/oncotarget.17841↗
  12. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreati… Co-author DOI 10.18632/oncotarget.10123↗
  13. Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. Last author DOI 10.18632/oncotarget.11530↗
  14. Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma. Co-author PMID 26851005↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Song Cheol Kim · 10 shared papers, 2016–2025 · strength 0.93
  2. Dong Woo Son · 2 shared papers, 2026 · strength 0.59
  3. Seung‐Mo Hong · 5 shared papers, 2016–2022 · strength 0.37
  4. Eun Ah Choi · 3 shared papers, 2018–2022 · strength 0.32
  5. Ye Jin Lim · 1 shared paper, 2026 · strength 0.30
  6. InKi Kim · 1 shared paper, 2025 · strength 0.26
  7. So Young Kim · 1 shared paper, 2025 · strength 0.26
  8. Jae Yun Jung · 2 shared papers, 2021–2022 · strength 0.24
  9. Yeon‐Sook Choi · 2 shared papers, 2018–2022 · strength 0.20
  10. Mi‐Ju Kim · 2 shared papers, 2017–2022 · strength 0.18
  11. Kyu‐pyo Kim · 2 shared papers, 2017–2021 · strength 0.18
  12. Inki Kim · 2 shared papers, 2017–2018 · strength 0.15
  13. Kihak Lee · 1 shared paper, 2021 · strength 0.14
  14. In Kyong Shim · 2 shared papers, 2016–2018 · strength 0.13
  15. Eunsung Jun · 2 shared papers, 2016–2018 · strength 0.13
  16. Robert M. Hoffman · 2 shared papers, 2016–2018 · strength 0.13
  17. Yeon Wook Kim · 1 shared paper, 2022 · strength 0.12
  18. So Young Kim · 1 shared paper, 2017 · strength 0.07
  19. Hosub Park · 1 shared paper, 2017 · strength 0.06
  20. Dae Wook Hwang · 1 shared paper, 2017 · strength 0.06
  21. Sung Joo Kim · 1 shared paper, 2017 · strength 0.06
  22. Eun Kyung Choi · 1 shared paper, 2016 · strength 0.05
  23. Changmo Hwang · 1 shared paper, 2016 · strength 0.05
  24. Jaeyun Jung · 1 shared paper, 2016 · strength 0.05
  25. Jinhoi Song · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.